According to MLI Managing Director Brian Lee Crowley, “MLI is fortunate to have worked with Nigel Rawson and John Adams extensively in recent years; they are precisely the kind of world-class thought leaders that we at MLI aim to attract and cultivate.
“As Canada presses forward with an unnecessary, costly, and counterproductive approach to drug policy, Canadians will depend even more on the warnings that Rawson and Adams have long provided.”
Nigel Rawson is a pharmacoepidemiologist and pharmaceutical policy researcher based in Saskatoon. He has performed epidemiologic studies on the use of drugs and their outcomes for over 40 years and was a founding member of the Canadian Association for Population Therapeutics, as well as president of Eastlake Research Group.
“Nigel Rawson brings to the Institute formidable and grounded knowledge on pharmaceutical policy,” notes Aaron Wudrick, MLI Domestic Policy Director. “His academic and private sector experience has given him expertise that MLI is excited to welcome.”
John Adams is an experienced management consultant with an extensive record in public policy. Adams is the co-founder, CEO and President of CanPKU, founding member and board chair of the Global Association for PKU, volunteers as the Board Chair of the Best Medicines Coalition, is co-chair of the Disability Tax Fairness Alliance and, as a hobby, represents individuals unjustly denied the Disability Tax Credit.
“John Adams brings a wealth of knowledge and experience in the Canadian health care system to the Institute,” says Wudrick. “His many years of work in this area makes him a great addition to MLI and an important voice Canada needs to hear.”
For more information, media are invited to contact:
Communications and Digital Media Manager